{"entity":{"id":"mitch-dowsett","kind":"person","name":"Mitch Dowsett","aka":[],"tldr":"The translational scientist behind the aromatase inhibitor era and the Ki67 response test used in POETIC.","summary":"Mitch Dowsett's laboratory established the pharmacology of aromatase inhibitors and the biomarker work that supported the ATAC trial, and defined Ki67 change after two weeks of endocrine therapy as a predictor of outcome (POETIC). He chaired the International Ki67 Working Group and led the IMPACT and POETIC trials with Ian Smith. His current work focuses on endocrine resistance biology and biomarker standardisation.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dowsett%20M%5BAuthor%5D%20Ki67%20endocrine"}],"tags":["breast","biomarkers","translational"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["endocrine-therapy","histopathology-ihc"],"targets":["estrogen-receptor"],"drugs":[],"companies":[],"institutions":["icr-london","royal-marsden"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Biochemical Endocrinology, Institute of Cancer Research and Royal Marsden","institutionId":"icr-london","specialisms":["Endocrine therapy biology","Ki67 and biomarkers","Aromatase inhibitors","Translational breast research"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dowsett%20M%5BAuthor%5D%20Ki67%20endocrine"}],"papers":[{"title":"Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group","journal":"JNCI","year":2021,"doi":"10.1093/jnci/djaa201"},{"title":"Peri-operative aromatase inhibitor treatment in determining or predicting longterm outcome in early breast cancer (POETIC)","journal":"Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(20)30458-7"}],"orcid":"0000-0003-4122-744X"},"route":"/people/mitch-dowsett/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"},{"id":"histopathology-ihc","kind":"technology","name":"Histopathology & immunohistochemistry","route":"/technologies/histopathology-ihc/"}],"target":[{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/"}],"institution":[{"id":"icr-london","kind":"institution","name":"The Institute of Cancer Research","route":"/institutions/icr-london/"},{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","route":"/institutions/royal-marsden/"}]}}